Anemia, particularly when resulting from chronic conditions or frequent blood transfusions, often leads to a dangerous buildup of iron in the body. Effectively managing this iron overload is crucial for patient health, and this is where pharmaceutical intermediates like Deferasirox (CAS: 201530-41-8) play a vital role. As a key component in iron chelation therapy, Deferasirox is instrumental in alleviating the complications associated with excess iron accumulation, making it a cornerstone in the treatment of various anemias.

Deferasirox acts as an oral iron chelator, meaning it binds to iron in the bloodstream and facilitates its excretion from the body. This process is particularly important for individuals with transfusion-dependent anemias, such as thalassemia, who receive regular blood transfusions. These transfusions, while life-saving, also introduce iron into the body, and without effective chelation, this iron can accumulate in vital organs like the heart, liver, and endocrine glands, leading to severe damage and dysfunction. The chemical properties of Deferasirox—its molecular formula C21H15N3O4 and molecular weight of 373.362 g/mol—are optimized for this binding and excretion process.

From a pharmaceutical manufacturing standpoint, Deferasirox is supplied as a high-purity powder, often exceeding 97% purity. This is essential for its intended use as an active pharmaceutical ingredient (API) in oral dosage forms. The typical white or pale yellow appearance and a melting point of 260-262°C are indicators of its quality and stability. Pharmaceutical companies rely on manufacturers to supply Deferasirox that consistently meets these specifications, ensuring the efficacy and safety of the final medicinal product.

The availability of Deferasirox from reliable suppliers is a significant factor for healthcare providers and patients. Procurement managers actively seek out manufacturers who can provide a stable supply chain, competitive pricing, and excellent customer support. Whether purchasing small quantities for research or large volumes for commercial production, securing this essential pharmaceutical intermediate from a trusted source is paramount. Understanding the application of Deferasirox, its chemical nature, and its availability as a product from reputable manufacturers empowers informed decision-making in healthcare supply chains.

In conclusion, Deferasirox (CAS 201530-41-8) is an indispensable pharmaceutical intermediate in the management of anemia-related iron overload. Its function as an oral iron chelator directly impacts patient outcomes, making its reliable sourcing and high quality essential. For those in the pharmaceutical industry seeking this critical compound, prioritizing manufacturers who adhere to stringent quality standards ensures the development of safe and effective treatments. We are dedicated to being a premier supplier of Deferasirox, supporting the ongoing efforts to combat iron overload and improve the lives of patients suffering from anemia.